{"id":"NCT02039726","sponsor":"Daiichi Sankyo","briefTitle":"(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive","officialTitle":"A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2018-02-22","completion":"2020-09-08","firstPosted":"2014-01-20","resultsPosted":"2020-01-27","lastUpdate":"2021-02-24"},"enrollment":367,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["AML"],"interventions":[{"type":"DRUG","name":"Quizartinib","otherNames":["AC220"]},{"type":"DRUG","name":"Salvage Chemotherapy","otherNames":["Standard of Care"]}],"arms":[{"label":"Quizartinib","type":"EXPERIMENTAL"},{"label":"Salvage chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 months, after first-line AML therapy.","primaryOutcome":{"measure":"Overall Survival in Participants That Received Quizartinib Versus Salvage Chemotherapy","timeFrame":"At approximately 3 years 9 months","effectByArm":[{"arm":"Quizartinib","deltaMin":27,"sd":null},{"arm":"Salvage Chemotherapy","deltaMin":20.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0185"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":131,"countries":["United States","Australia","Belgium","Canada","Croatia","Czechia","France","Germany","Hong Kong","Hungary","Italy","Netherlands","Poland","Serbia","Singapore","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["33415416","31175001","29859851"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":168,"n":241},"commonTop":["Nausea","Pyrexia","Anemia","Diarrhea","Hypokalemia"]}}